Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)

被引：1
|
作者：
Pavel, M. E. [1 ]
von Weikersthal, L. Fischer [2 ]
Kloeppel, G. [3 ]
Krause, K. [4 ]
Apostolidis, L. [5 ]
机构：
[1] Univ Klin Erlangen, Endocrinol Dept, Gastroenterol & Hepatol, Erlangen, Germany
[2] Klinikum St Marien Amberg, Onkolog Zentrum, Amberg, Germany
[3] Tech Univ Munich, Inst Pathol, Munich, Germany
[4] AIO Studien gGmbH, Project Management Dept, Berlin, Germany
[5] Natl Ctr Tumor Dis NCT, Dept Med Oncol, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1184MO
引用
收藏
页码：S702 / S702
页数：1
相关论文
共 50 条
  • [41] Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment
    Zhang, Ming-Yi
    He, Du
    Zhang, Shuang
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (07) : 705 - 718
  • [42] Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment
    Ming-Yi Zhang
    Du He
    Shuang Zhang
    World Journal of Gastrointestinal Oncology, 2020, 12 (07) : 705 - 718
  • [43] Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN).
    Dreyer, Chantal
    Couvelard, Anne
    Walter, Thomas
    Bohas, Catherine Lombard
    Niccoli, Patricia
    Seitz, Jean-Francois
    Hentic, Olivia
    Pellat, Anna
    Andre, Thierry
    Couffignat, Camille
    Lobbe, Nathalie
    Mentre, France
    Bedossa, Pierre
    Hammel, Pascal
    Faivre, Sandrine J.
    Zappa, Magalie
    Ruszniewski, Philippe B.
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [44] Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3
    Koenig, A. O.
    Reinecke, J.
    Halfen, J.
    Lang, K.
    Koenig, U.
    Tostmann, R.
    Kirchhof, N.
    Asendorf, T.
    Hoersch, D.
    Kroecher, A.
    Quante, M.
    Ellenrieder, V.
    Schulte, N.
    Wirth, T.
    Weich, A.
    Apostolidis, L.
    Krug, S.
    Rinke, A.
    Pavel, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S752 - S752
  • [45] Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
    Cameselle-Garcia, S.
    Sardo, E.
    Landolfi, S.
    Merino-Casabiel, X.
    Sanchez, J. L.
    Balsells, J.
    Pando, E.
    Blanco, L.
    Diez, M.
    Acosta, D.
    Capdevila, J.
    Hernando, J.
    NEUROENDOCRINOLOGY, 2020, 110 : 64 - 64
  • [46] Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3
    Hinterleitner, Martina
    Pfeiffer, Ruben
    Trautwein, Nils F.
    Sipos, Bence
    Singer, Stephan
    Nadalin, Silvio
    Koenigsrainer, Alfred
    Lauer, Ulrich M.
    la Fougere, Christian
    Zender, Lars
    Hinterleitner, Clemens
    FRONTIERS IN ENDOCRINOLOGY, 2024, 14
  • [47] Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors
    Olsen, I. H.
    Borbath, I
    Heetfeld, M.
    Walter, T.
    Barriuso, J.
    O'Toole, D.
    Pavel, M.
    Chougnet, C.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 233 - 233
  • [48] Clinicopathological characteristics and treatment options of the new grade 3 neuroendocrine tumor subgroup (NETs G3)
    Evdokimova, E.
    Artamonova, E.
    Chemeris, G.
    Yemelyanova, G.
    Markovich, A.
    Delektorskaya, V
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 174 - 174
  • [49] Multicenter analysis of treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3).
    Apostolidis, Leonidas
    Dal Buono, Arianna
    Merola, Elettra
    Jann, Henning
    Jaeger, Dirk
    Wiedenmann, Bertram
    Winkler, Eva Caroline
    Pavel, Marianne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Efficacy and safety of Surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Preliminary results from a single-arm, phase II study
    Wang, W.
    Liu, Z.
    Yang, X.
    Xue, Z.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 255 - 255
12345